The DOI matches its Crossref record; 207 of the 207 references it cites were found in a registry or an index.
Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors
Open accessAbstract
Natural killer (NK) cells are a population of innate lymphoid cells playing a pivotal role in host immune responses against infection and tumor growth. These cells have a powerful cytotoxic activity orchestrated by an intricate network of inhibitory and activating signals. The importance of NK cells in controlling tumor growth and in mediating a robust anti-metastatic effect has been demonstrated in different experimental mouse cancer models. Consistently, high density of tumor-infiltrating NK cells has been linked with a good prognosis in multiple human solid tumors. However, there are also tumors that appear to be refractory to NK cell-mediated killing for the presence of an immunosuppressive microenvironment affecting NK cell function. Immunotherapeutic strategies aimed at restoring and increasing the cytotoxic activity of NK cells in solid tumors, including the adoptive transfer of NK and CAR-NK cells, are currently employed in preclinical and clinical studies. In this review, we outline recent advances supporting the direct role of NK cells in controlling expansion of solid tumors and their prognostic value in human cancers. We summarize the mechanisms adopted by cancer cells and the tumor microenvironment to affect NK cell function, and finally we evaluate current strategies to augment the antitumor function of NK cells for the treatment of solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
NK cell heparanase controls tumor invasion and immune surveillance
Putz, E. M., Mayfosh, A. J., Kos, K., Barkauskas, D. S., Nakamura, K., Town, L., Goodall, K. J., Yee, D. Y., Poon, I. K. H., Baschuk, N., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92958 · Cited by 105
RetractedZhu, L., Oh, J. M., Gangadaran, P., Kalimuthu, S., Baek, S. H., Jeong, S. Y., Lee, S., Lee, J., & Ahn, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00824 · Cited by 88
RetractedMantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331
Transforming Growth Factor-β Signaling in Immunity and Cancer
Batlle, E., & Massagué, J. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.024 · Cited by 2,366
Denkert, C., von Minckwitz, G., Darb-Esfahani, S., Lederer, B., Heppner, B. I., Weber, K. E., Budczies, J., Huober, J., Klauschen, F., Furlanetto, J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30904-x · Cited by 2,157
Miller, J. S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D., Le, C., Defor, T. E., Burns, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2974 · Cited by 1,903
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D., & Sotomayor, E. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,702
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
Groh, V., Wu, J., Yee, C., & Spies, T. (2002) · Nature · doi:10.1038/nature01112 · Cited by 1,592
Regulation of Immune Responses by Prostaglandin E2
Kalinski, P. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101029 · Cited by 1,474
Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses
Ho, P.-C., Bihuniak, J. D., Macintyre, A. N., Staron, M., Liu, X., Amezquita, R., Tsui, Y.-C., Cui, G., Micevic, G., Perales, J. C., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.012 · Cited by 1,462
Direct Recognition of Cytomegalovirus by Activating and Inhibitory NK Cell Receptors
Arase, H., Mocarski, E. S., Campbell, A. E., Hill, A. B., & Lanier, L. L. (2002) · Science · doi:10.1126/science.1070884 · Cited by 1,230
Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses
Lavin, Y., Kobayashi, S., Leader, A., Amir, E.-A. D., Elefant, N., Bigenwald, C., Remark, R., Sweeney, R., Becker, C. D., Levine, J. H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.04.014 · Cited by 1,209
Natural Killer Cells: Development, Maturation, and Clinical Utilization
Abel, A. M., Yang, C., Thakar, M. S., & Malarkannan, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01869 · Cited by 1,150
Spaggiari, G. M., Capobianco, A., Abdelrazik, H., Becchetti, F., Mingari, M. C., & Moretta, L. (2008) · Blood · doi:10.1182/blood-2007-02-074997 · Cited by 1,146
Frumento, G., Rotondo, R., Tonetti, M., Damonte, G., Benatti, U., & Ferrara, G. B. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020121 · Cited by 1,133
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity
Zelenay, S., van der Veen, A. G., Böttcher, J. P., Snelgrove, K. J., Rogers, N., Acton, S. E., Chakravarty, P., Girotti, M. R., Marais, R., Quezada, S. A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.015 · Cited by 1,128
Zhang, Q., Bi, J., Zheng, X., Chen, Y., Wang, H., Wu, W., Wang, Z., Wu, Q., Peng, H., Wei, H., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0132-0 · Cited by 1,122
Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
Diefenbach, A., Jensen, E. R., Jamieson, A. M., & Raulet, D. H. (2001) · Nature · doi:10.1038/35093109 · Cited by 1,083
Targeting natural killer cells in cancer immunotherapy
Guillerey, C., Huntington, N. D., & Smyth, M. J. (2016) · Nature Immunology · doi:10.1038/ni.3518 · Cited by 1,066
A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
Barry, K. C., Hsu, J., Broz, M. L., Cueto, F. J., Binnewies, M., Combes, A. J., Nelson, A. E., Loo, K., Kumar, R., Rosenblum, M. D., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0085-8 · Cited by 1,021
The hypoxic tumour microenvironment
Petrova, V., Annicchiarico-Petruzzelli, M., Melino, G., & Amelio, I. (2018) · Oncogenesis · doi:10.1038/s41389-017-0011-9 · Cited by 1,019
Role of Natural Killer Cell Alloreactivity in HLA-Mismatched Hematopoietic Stem Cell Transplantation
Ruggeri, L., Capanni, M., Casucci, M., Volpi, I., Tosti, A., Perruccio, K., Urbani, E., Negrin, R. S., Martelli, M. F., & Velardi, A. (1999) · Blood · doi:10.1182/blood.v94.1.333.413a31_333_339 · Cited by 994
Li, Y., Hermanson, D. L., Moriarity, B. S., & Kaufman, D. S. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.06.002 · Cited by 981
Hirayama, A., Kami, K., Sugimoto, M., Sugawara, M., Toki, N., Onozuka, H., Kinoshita, T., Saito, N., Ochiai, A., Tomita, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4806 · Cited by 956
Ghiringhelli, F., Ménard, C., Terme, M., Flament, C., Taieb, J., Chaput, N., Puig, P. E., Novault, S., Escudier, B., Vivier, E., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051511 · Cited by 949
Chromatin states define tumour-specific T cell dysfunction and reprogramming
Philip, M., Fairchild, L., Sun, L., Horste, E. L., Camara, S., Shakiba, M., Scott, A. C., Viale, A., Lauer, P., Merghoub, T., et al. (2017) · Nature · doi:10.1038/nature22367 · Cited by 933 · cited 1×
“Indeed, similarly to tumor-infiltrating T cells (103, 104), NK cells in the mouse lung cancer are functional during tumor initiation, while assume a mild dysfunctional state during tumor promotion that can be reverted by pharmacological FBP1 inhibition.”
BackgroundRegulation of Ligands for the NKG2D Activating Receptor
Raulet, D. H., Gasser, S., Gowen, B. G., Deng, W., & Jung, H. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095951 · Cited by 848
Husain, Z., Huang, Y., Seth, P., & Sukhatme, V. P. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202702 · Cited by 822
Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT
Malladi, S., Macalinao, D. G., Jin, X., He, L., Basnet, H., Zou, Y., de Stanchina, E., & Massagué, J. (2016) · Cell · doi:10.1016/j.cell.2016.02.025 · Cited by 791
Li, H., Han, Y., Guo, Q., Zhang, M., & Cao, X. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.1.240 · Cited by 777
Castriconi, R., Cantoni, C., Della Chiesa, M., Vitale, M., Marcenaro, E., Conte, R., Biassoni, R., Bottino, C., Moretta, L., & Moretta, A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0730640100 · Cited by 726
Metabolic Reprogramming of Immune Cells in Cancer Progression
Biswas, S. K. (2015) · Immunity · doi:10.1016/j.immuni.2015.09.001 · Cited by 721
Schietinger, A., Philip, M., Krisnawan, V. E., Chiu, E. Y., Delrow, J. J., Basom, R. S., Lauer, P., Brockstedt, D. G., Knoblaugh, S. E., Hämmerling, G. J., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.011 · Cited by 720 · cited 1×
“Indeed, similarly to tumor-infiltrating T cells (103, 104), NK cells in the mouse lung cancer are functional during tumor initiation, while assume a mild dysfunctional state during tumor promotion that can be reverted by pharmacological FBP1 inhibition.”
BackgroundTGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway
Viel, S., Marçais, A., Guimaraes, F. S.-F., Loftus, R., Rabilloud, J., Grau, M., Degouve, S., Djebali, S., Sanlaville, A., Charrier, E., et al. (2016) · Science Signaling · doi:10.1126/scisignal.aad1884 · Cited by 672
Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells
Gao, Y., Souza-Fonseca-Guimaraes, F., Bald, T., Ng, S. S., Young, A., Ngiow, S. F., Rautela, J., Straube, J., Waddell, N., Blake, S. J., et al. (2017) · Nature Immunology · doi:10.1038/ni.3800 · Cited by 654
Metabolic reprogramming of natural killer cells in obesity limits antitumor responses
Michelet, X., Dyck, L., Hogan, A., Loftus, R. M., Duquette, D., Wei, K., Beyaz, S., Tavakkoli, A., Foley, C., Donnelly, R., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0251-7 · Cited by 621
Lee, J.-C., Lee, K.-M., Kim, D.-W., & Heo, D. S. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.12.7335 · Cited by 549
Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy
Kishton, R. J., Sukumar, M., & Restifo, N. P. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.06.016 · Cited by 548
Arnould, L., Gelly, M., Penault-Llorca, F., Benoit, L., Bonnetain, F., Migeon, C., Cabaret, V, Fermeaux, V, Bertheau, P., Garnier, J., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602930 · Cited by 545
Xie, H., Hanai, J.-I., Ren, J.-G., Kats, L., Burgess, K., Bhargava, P., Signoretti, S., Billiard, J., Duffy, K. J., Grant, A., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.03.003 · Cited by 516
TGFβ is a master regulator of radiation therapy-induced antitumor immunity
Vanpouille-Box, C., Diamond, J. M., Pilones, K. A., Zavadil, J., Babb, J. S., Formenti, S. C., Barcellos-Hoff, M. H., & Demaria, S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3511 · Cited by 514
Macrophage Metabolism Controls Tumor Blood Vessel Morphogenesis and Metastasis
Wenes, M., Shang, M., Di Matteo, M., Goveia, J., Martín-Pérez, R., Serneels, J., Prenen, H., Ghesquière, B., Carmeliet, P., & Mazzone, M. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.09.008 · Cited by 496
Spiegel, A., Brooks, M. W., Houshyar, S., Reinhardt, F., Ardolino, M., Fessler, E., Chen, M. B., Krall, J. A., DeCock, J., Zervantonakis, I. K., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1157 · Cited by 476
Kopp, H.-G., Placke, T., & Salih, H. R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2123 · Cited by 469
Villegas, F. R., Coca, S., Villarrubia, V. G., Jiménez, R., Chillón, M. J., Jareño, J., Zuil, M., & Callol, L. (2002) · Lung Cancer · doi:10.1016/s0169-5002(01)00292-6 · Cited by 467
Adams, C. M., Reitz, J., De Brabander, J. K., Feramisco, J. D., Li, L., Brown, M. S., & Goldstein, J. L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m410302200 · Cited by 456
Immunometabolism and natural killer cell responses
O’Brien, K. L., & Finlay, D. K. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0139-2 · Cited by 435
Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
da Silva, I. P., Gallois, A., Jimenez-Baranda, S., Khan, S., Anderson, A. C., Kuchroo, V. K., Osman, I., & Bhardwaj, N. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0171 · Cited by 424
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
Vigano, S., Alatzoglou, D., Irving, M., Ménétrier-Caux, C., Caux, C., Romero, P., & Coukos, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00925 · Cited by 420
Tertiary lymphoid structures, drivers of the anti‐tumor responses in human cancers
Dieu‐Nosjean, M., Giraldo, N. A., Kaplon, H., Germain, C., Fridman, W. H., & Sautès‐Fridman, C. (2016) · Immunological Reviews · doi:10.1111/imr.12405 · Cited by 417
Effect of tumor cells and tumor microenvironment on NK‐cell function
Vitale, M., Cantoni, C., Pietra, G., Mingari, M. C., & Moretta, L. (2014) · European Journal of Immunology · doi:10.1002/eji.201344272 · Cited by 412
Wrangle, J. M., Velcheti, V., Patel, M. R., Garrett-Mayer, E., Hill, E. G., Ravenel, J. G., Miller, J. S., Farhad, M., Anderton, K., Lindsey, K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30148-7 · Cited by 412
Romee, R., Cooley, S., Berrien-Elliott, M. M., Westervelt, P., Verneris, M. R., Wagner, J. E., Weisdorf, D. J., Blazar, B. R., Ustun, C., DeFor, T. E., et al. (2018) · Blood · doi:10.1182/blood-2017-12-823757 · Cited by 409
Curti, A., Ruggeri, L., D'Addio, A., Bontadini, A., Dan, E., Motta, M. R., Trabanelli, S., Giudice, V., Urbani, E., Martinelli, G., et al. (2011) · Blood · doi:10.1182/blood-2011-01-329508 · Cited by 406
Chiesa, M. D., Carlomagno, S., Frumento, G., Balsamo, M., Cantoni, C., Conte, R., Moretta, L., Moretta, A., & Vitale, M. (2006) · Blood · doi:10.1182/blood-2006-03-006700 · Cited by 399
Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities
Hu, W., Wang, G., Huang, D., Sui, M., & Xu, Y. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01205 · Cited by 398
ATP-citrate lyase controls a glucose-to-acetate metabolic switch
Zhao, S., Torres, A., Henry, R. A., Trefely, S., Wallace, M., Lee, J. V., Carrer, A., Sengupta, A., Campbell, S. L., Kuo, Y.-M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.069 · Cited by 394
A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment
Young, A., Ngiow, S. F., Gao, Y., Patch, A.-M., Barkauskas, D. S., Messaoudene, M., Lin, G., Coudert, J. D., Stannard, K. A., Zitvogel, L., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2826 · Cited by 391
ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
Zhang, C., Burger, M. C., Jennewein, L., Genßler, S., Schönfeld, K., Zeiner, P., Hattingen, E., Harter, P. N., Mittelbronn, M., Tonn, T., et al. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv375 · Cited by 388
Cong, J., Wang, X., Zheng, X., Wang, D., Fu, B., Sun, R., Tian, Z., & Wei, H. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.06.021 · Cited by 380
Carrega, P., Morandi, B., Costa, R., Frumento, G., Forte, G., Altavilla, G., Ratto, G. B., Mingari, M. C., Moretta, L., & Ferlazzo, G. (2008) · Cancer · doi:10.1002/cncr.23239 · Cited by 379
Srebp-controlled glucose metabolism is essential for NK cell functional responses
Assmann, N., O'Brien, K. L., Donnelly, R. P., Dyck, L., Zaiatz-Bittencourt, V., Loftus, R. M., Heinrich, P., Oefner, P. J., Lynch, L., Gardiner, C. M., et al. (2017) · Nature Immunology · doi:10.1038/ni.3838 · Cited by 375
The Natural Cytotoxicity Receptors in Health and Disease
Barrow, A. D., Martin, C. J., & Colonna, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00909 · Cited by 370
Liu, Y., Cheng, Y., Xu, Y., Wang, Z., Du, X., Li, C., Peng, J., Gao, L., Liang, X., & Ma, C. (2017) · Oncogene · doi:10.1038/onc.2017.209 · Cited by 366
Sceneay, J., Chow, M. T., Chen, A., Halse, H. M., Wong, C. S. F., Andrews, D. M., Sloan, E. K., Parker, B. S., Bowtell, D. D., Smyth, M. J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3873 · Cited by 364
Harmon, C., Robinson, M. W., Hand, F., Almuaili, D., Mentor, K., Houlihan, D. D., Hoti, E., Lynch, L., Geoghegan, J., & O'Farrelly, C. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0481 · Cited by 360
Holmgaard, R. B., Schaer, D. A., Li, Y., Castaneda, S. P., Murphy, M. Y., Xu, X., Inigo, I., Dobkin, J., Manro, J. R., Iversen, P. W., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0356-4 · Cited by 356
Schönfeld, K., Sahm, C., Zhang, C., Naundorf, S., Brendel, C., Odendahl, M., Nowakowska, P., Bönig, H., Köhl, U., Kloess, S., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.219 · Cited by 348
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors
Delahaye, N. F., Rusakiewicz, S., Martins, I., Ménard, C., Roux, S., Lyonnet, L., Paul, P., Sarabi, M., Chaput, N., Semeraro, M., et al. (2011) · Nature Medicine · doi:10.1038/nm.2366 · Cited by 341
NK Cells Recognize and Kill Human Glioblastoma Cells with Stem Cell-Like Properties
Castriconi, R., Daga, A., Dondero, A., Zona, G., Poliani, P. L., Melotti, A., Griffero, F., Marubbi, D., Spaziante, R., Bellora, F., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802845 · Cited by 337
Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity
Balsamo, M., Scordamaglia, F., Pietra, G., Manzini, C., Cantoni, C., Boitano, M., Queirolo, P., Vermi, W., Facchetti, F., Moretta, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906481106 · Cited by 330
Ravi, R., Noonan, K. A., Pham, V., Bedi, R., Zhavoronkov, A., Ozerov, I. V., Makarev, E., V. Artemov, A., Wysocki, P. T., Mehra, R., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02696-6 · Cited by 325
Metabolic Reprogramming Supports IFN-γ Production by CD56bright NK Cells
Keating, S. E., Zaiatz-Bittencourt, V., Loftus, R. M., Keane, C., Brennan, K., Finlay, D. K., & Gardiner, C. M. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501783 · Cited by 325
Pietra, G., Manzini, C., Rivara, S., Vitale, M., Cantoni, C., Petretto, A., Balsamo, M., Conte, R., Benelli, R., Minghelli, S., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2544 · Cited by 324
TGF- downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients
Crane, C. A., Han, S. J., Barry, J. J., Ahn, B. J., Lanier, L. L., & Parsa, A. T. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop009 · Cited by 322
Natural killer cells and cancer
Brittenden, J., Heys, S. D., Ross, J., & Eremin, O. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960401)77:7<1226::aid-cncr2>3.0.co;2-g · Cited by 319
Zhang, C., Oberoi, P., Oelsner, S., Waldmann, A., Lindner, A., Tonn, T., & Wels, W. S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00533 · Cited by 306
NK cell-based immunotherapy for cancer
Fang, F., Xiao, W., & Tian, Z. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.07.009 · Cited by 306
Friese, M. A., Wischhusen, J., Wick, W., Weiler, M., Eisele, G., Steinle, A., & Weller, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1627 · Cited by 305
Halama, N., Braun, M., Kahlert, C., Spille, A., Quack, C., Rahbari, N., Koch, M., Weitz, J., Kloor, M., Zoernig, I., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2173 · Cited by 300
Cursons, J., Souza-Fonseca-Guimaraes, F., Foroutan, M., Anderson, A., Hollande, F., Hediyeh-Zadeh, S., Behren, A., Huntington, N. D., & Davis, M. J. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0500 · Cited by 296
Melisi, D., Garcia-Carbonero, R., Macarulla, T., Pezet, D., Deplanque, G., Fuchs, M., Trojan, J., Oettle, H., Kozloff, M., Cleverly, A., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0246-z · Cited by 294
Accelerated tumor growth in mice deficient in DNAM-1 receptor
Iguchi-Manaka, A., Kai, H., Yamashita, Y., Shibata, K., Tahara-Hanaoka, S., Honda, S.-I., Yasui, T., Kikutani, H., Shibuya, K., & Shibuya, A. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20081611 · Cited by 290
Cai, L., Zhang, Z., Zhou, L., Wang, H., Fu, J., Zhang, S., Shi, M., Zhang, H., Yang, Y., Wu, H., et al. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.08.012 · Cited by 288
Balsamo, M., Manzini, C., Pietra, G., Raggi, F., Blengio, F., Mingari, M. C., Varesio, L., Moretta, L., Bosco, M. C., & Vitale, M. (2013) · European Journal of Immunology · doi:10.1002/eji.201343448 · Cited by 282
Klein, C., Waldhauer, I., Nicolini, V. G., Freimoser-Grundschober, A., Nayak, T., Vugts, D. J., Dunn, C., Bolijn, M., Benz, J., Stihle, M., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1277306 · Cited by 281
Natural Killer Cells Control Tumor Growth by Sensing a Growth Factor
Barrow, A. D., Edeling, M. A., Trifonov, V., Luo, J., Goyal, P., Bohl, B., Bando, J. K., Kim, A. H., Walker, J., Andahazy, M., et al. (2018) · Cell · doi:10.1016/j.cell.2017.11.037 · Cited by 280
Trotta, R., Col, J. D., Yu, J., Ciarlariello, D., Thomas, B., Zhang, X., Allard, J., Wei, M., Mao, H., Byrd, J. C., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.6.3784 · Cited by 275
Mao, Y., Sarhan, D., Steven, A., Seliger, B., Kiessling, R., & Lundqvist, A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0635 · Cited by 274
The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer
Rezvani, K., & Rouce, R. H. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00578 · Cited by 272
Wu, Y., Kuang, D.-M., Pan, W.-D., Wan, Y.-L., Lao, X.-M., Wang, D., Li, X.-F., & Zheng, L. (2013) · Hepatology · doi:10.1002/hep.26192 · Cited by 266
Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer
Formenti, S. C., Lee, P., Adams, S., Goldberg, J. D., Li, X., Xie, M. W., Ratikan, J. A., Felix, C., Hwang, L., Faull, K. F., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3322 · Cited by 257
Cortez, V. S., Cervantes-Barragan, L., Robinette, M. L., Bando, J. K., Wang, Y., Geiger, T. L., Gilfillan, S., Fuchs, A., Vivier, E., Sun, J. C., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.03.007 · Cited by 255
Tallerico, R., Todaro, M., Di Franco, S., Maccalli, C., Garofalo, C., Sottile, R., Palmieri, C., Tirinato, L., Pangigadde, P. N., La Rocca, R., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201542 · Cited by 251
Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy
Blake, S. J., Stannard, K., Liu, J., Allen, S., Yong, M. C. R., Mittal, D., Aguilera, A. R., Miles, J. J., Lutzky, V. P., de Andrade, L. F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0944 · Cited by 243
Chen, X., Han, J., Chu, J., Zhang, L., Zhang, J., Chen, C., Chen, L., Wang, Y., Wang, H., Yi, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8526 · Cited by 242
Targeting natural killer cells in solid tumors
Habif, G., Crinier, A., André, P., Vivier, E., & Narni-Mancinelli, E. (2019) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0224-2 · Cited by 241
Bastid, J., Regairaz, A., Bonnefoy, N., Déjou, C., Giustiniani, J., Laheurte, C., Cochaud, S., Laprevotte, E., Funck-Brentano, E., Hemon, P., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0018 · Cited by 240
Jong, A. Y., Wu, C., Li, J., Sun, J., Fabbri, M., Wayne, A. S., & Seeger, R. C. (2017) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2017.1294368 · Cited by 239
NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype
Ames, E., Canter, R. J., Grossenbacher, S. K., Mac, S., Chen, M., Smith, R. C., Hagino, T., Perez-Cunningham, J., Sckisel, G. D., Urayama, S., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500447 · Cited by 235
IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity
Molgora, M., Bonavita, E., Ponzetta, A., Riva, F., Barbagallo, M., Jaillon, S., Popović, B., Bernardini, G., Magrini, E., Gianni, F., et al. (2017) · Nature · doi:10.1038/nature24293 · Cited by 226
Han, K.-P., Zhu, X., Liu, B., Jeng, E., Kong, L., Yovandich, J. L., Vyas, V. V., Marcus, W. D., Chavaillaz, P.-A., Romero, C. A., et al. (2011) · Cytokine · doi:10.1016/j.cyto.2011.09.028 · Cited by 223
Molecular pathways: targeting CD96 and TIGIT for cancer immunotherapy
Blake, S. J., Dougall, W. C., Miles, J. J., Teng, M. W. L., & Smyth, M. J. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0933 · Cited by 223
TGF-β–inducible microRNA-183 silences tumor-associated natural killer cells
Donatelli, S. S., Zhou, J.-M., Gilvary, D. L., Eksioglu, E. A., Chen, X., Cress, W. D., Haura, E. B., Schabath, M. B., Coppola, D., Wei, S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319269111 · Cited by 221
Sarkar, S., Germeraad, W. T. V., Rouschop, K. M. A., Steeghs, E. M. P., Gelder, M. V., Bos, G. M. J., & Wieten, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064835 · Cited by 215
Handgretinger, R., Anderson, K., Lang, P., Dopfer, R., Klingebiel, T., Schrappe, M., Reuland, P., Gillies, S. D., Reisfeld, R. A., & Niethammer, D. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(94)00413-y · Cited by 213
The Role of CXC Chemokine Receptors 1–4 on Immune Cells in the Tumor Microenvironment
Susek, K. H., Karvouni, M., Alici, E., & Lundqvist, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02159 · Cited by 212
Pasero, C., Gravis, G., Guerin, M., Granjeaud, S., Thomassin-Piana, J., Rocchi, P., Paciencia-Gros, M., Poizat, F., Bentobji, M., Azario-Cheillan, F., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1965 · Cited by 209
Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors
Margolin, K., Morishima, C., Velcheti, V., Miller, J. S., Lee, S. M., Silk, A. W., Holtan, S. G., Lacroix, A. M., Fling, S. P., Kaiser, J. C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0945 · Cited by 208
Ménard, C., Blay, J.-Y., Borg, C., Michiels, S., Ghiringhelli, F., Robert, C., Nonn, C., Chaput, N., Taïeb, J., Delahaye, N. F., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3807 · Cited by 202
Xu, W., Jones, M., Liu, B., Zhu, X., Johnson, C. B., Edwards, A. C., Kong, L., Jeng, E. K., Han, K., Marcus, W. D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2357 · Cited by 198
Veluchamy, J. P., Kok, N., van der Vliet, H. J., Verheul, H. M. W., de Gruijl, T. D., & Spanholtz, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00631 · Cited by 197
Miller, J. S., Morishima, C., McNeel, D. G., Patel, M. R., Kohrt, H. E. K., Thompson, J. A., Sondel, P. M., Wakelee, H. A., Disis, M. L., Kaiser, J. C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2451 · Cited by 197
Häusler, S. F. M., Montalbán del Barrio, I., Strohschein, J., Anoop Chandran, P., Engel, J. B., Hönig, A., Ossadnik, M., Horn, E., Fischer, B., Krockenberger, M., et al. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1040-4 · Cited by 193
The Prognostic Significance of Natural Killer Cytotoxicity in Patients With Colorectal Cancer
Tartter, P. I. (1987) · Archives of Surgery · doi:10.1001/archsurg.1987.01400230050009 · Cited by 191
Esser, R., Müller, T., Stefes, D., Kloess, S., Seidel, D., Gillies, S. D., Aperlo‐Iffland, C., Huston, J. S., Uherek, C., Schönfeld, K., et al. (2012) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01343.x · Cited by 188
Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells
Sathe, P., Delconte, R. B., Souza-Fonseca-Guimaraes, F., Seillet, C., Chopin, M., Vandenberg, C. J., Rankin, L. C., Mielke, L. A., Vikstrom, I., Kolesnik, T. B., et al. (2014) · Nature Communications · doi:10.1038/ncomms5539 · Cited by 187
Thompson, J. A., Curti, B. D., Redman, B. G., Bhatia, S., Weber, J. S., Agarwala, S. S., Sievers, E. L., Hughes, S. D., DeVries, T. A., & Hausman, D. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5193 · Cited by 187
Sahm, C., Schönfeld, K., & Wels, W. S. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1212-x · Cited by 186
Jochems, C., Hodge, J. W., Fantini, M., Fujii, R., Morillon, Y. M., Greiner, J. W., Padget, M. R., Tritsch, S. R., Yok Tsang, K., Campbell, K. S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13411 · Cited by 182
IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells
Parihar, R., Dierksheide, J., Hu, Y., & Carson, W. E. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15950 · Cited by 180
Ma, S.-R., Deng, W.-W., Liu, J.-F., Mao, L., Yu, G.-T., Bu, L.-L., Kulkarni, A. B., Zhang, W.-F., & Sun, Z.-J. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0665-0 · Cited by 179
Dodagatta-Marri, E., Meyer, D. S., Reeves, M. Q., Paniagua, R., To, M. D., Binnewies, M., Broz, M. L., Mori, H., Wu, D., Adoumie, M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0493-9 · Cited by 177
Recognition and Prevention of Tumor Metastasis by the NK Receptor NKp46/NCR1
Glasner, A., Ghadially, H., Gur, C., Stanietsky, N., Tsukerman, P., Enk, J., & Mandelboim, O. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102461 · Cited by 176
Holt, D., Ma, X., Kundu, N., & Fulton, A. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1064-9 · Cited by 171
CAR T Cell Therapy for Neuroblastoma
Richards, R. M., Sotillo, E., & Majzner, R. G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02380 · Cited by 168
Cancer Stem Cells and Their Microenvironment: Biology and Therapeutic Implications
Lau, E. Y.-T., Ho, N. P.-Y., & Lee, T. K.-W. (2017) · Stem Cells International · doi:10.1155/2017/3714190 · Cited by 167
Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients
Semeraro, M., Rusakiewicz, S., Minard‐Colin, V., Delahaye, N. F., Enot, D. P., Vely, F., Marabelle, A., Papoular, B., Pipéroglou, C., Ponzoni, M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa2327 · Cited by 164
IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells
Parihar, R., Dierksheide, J., Hu, Y., & Carson, W. E. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215950 · Cited by 164
Park, A., Lee, Y., Kim, M. S., Kang, Y. J., Park, Y.-J., Jung, H., Kim, T.-D., Lee, H. G., Choi, I., & Yoon, S. R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01859 · Cited by 163
GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity
Cichocki, F. M., Valamehr, B. B., Bjordahl, R., Zhang, B., Rezner, B., Rogers, P., Gaidarova, S., Moreno, S. K., Tuininga, K., Dougherty, P., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0799 · Cited by 162
Tumor-derived lactate and myeloid-derived suppressor cells: Linking metabolism to cancer immunology
Husain, Z., Seth, P., & Sukhatme, V. (2013) · OncoImmunology · doi:10.4161/onci.26383 · Cited by 161
PGE2 induced in and released by dying cells functions as an inhibitory DAMP
Hangai, S., Ao, T., Kimura, Y., Matsuki, K., Kawamura, T., Negishi, H., Nishio, J., Kodama, T., Taniguchi, T., & Yanai, H. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1602023113 · Cited by 161
The immunocytokine NHS-IL12 as a potential cancer therapeutic
Fallon, J., Tighe, R., Kradjian, G., Guzman, W., Bernhardt, A., Neuteboom, B., Lan, Y., Sabzevari, H., Schlom, J., & Greiner, J. W. (2014) · Oncotarget · doi:10.18632/oncotarget.1853 · Cited by 160
Neuroblastoma-Derived TGF-β1 Modulates the Chemokine Receptor Repertoire of Human Resting NK Cells
Castriconi, R., Dondero, A., Bellora, F., Moretta, L., Castellano, A., Locatelli, F., Corrias, M. V., Moretta, A., & Bottino, C. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202693 · Cited by 159
Natural killer cells kill human melanoma cells with characteristics of cancer stem cells
Pietra, G., Manzini, C., Vitale, M., Balsamo, M. L., Ognio, E., Boitano, M., Queirolo, P., Moretta, L., & Mingari, M. C. (2009) · International Immunology · doi:10.1093/intimm/dxp047 · Cited by 158
Schleypen, J. S., Baur, N., Kammerer, R., Nelson, P. J., Rohrmann, K., Gröne, E., Hohenfellner, M., Haferkamp, A., Pohla, H., Schendel, D. J., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0857 · Cited by 156
Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions
Xu, F., Sunderland, A., Zhou, Y., Schulick, R. D., Edil, B. H., & Zhu, Y. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2031-x · Cited by 152
Gilman, A. L., Ozkaynak, M. F., Matthay, K. K., Krailo, M., Yu, A. L.-T., Gan, J., Sternberg, A. G., Hank, J. A., Seeger, R. C., Reaman, G. H., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.3564 · Cited by 151
Vey, N., Karlin, L., Sadot‐Lebouvier, S., Broussais, F., Berton-Rigaud, D., Rey, J., Charbonnier, A., Marie, D., André, P., Paturel, C., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24832 · Cited by 149
Rosario, M., Liu, B., Kong, L., Collins, L. I., Schneider, S. E., Chen, X., Han, K., Jeng, E. K., Rhode, P. R., Leong, J. W., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1419 · Cited by 147
Ali, T. H., Pisanti, S., Ciaglia, E., Mortarini, R., Anichini, A., Garofalo, C., Tallerico, R., Santinami, M., Gulletta, E., Ietto, C., et al. (2014) · Nature Communications · doi:10.1038/ncomms6639 · Cited by 145
Eckl, J., Büchner, A., Prinz, P. U., Riesenberg, R., Siegert, S. I., Kammerer, R., Nelson, P. J., & Noeßner, E. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0806-7 · Cited by 142
Simon, T., Hero, B., Faldum, A., Handgretinger, R., Schrappe, M., NIETHAMMER, D., & Berthold, F. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.143 · Cited by 141
Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II Study
Petrella, T. M., Tozer, R. G., Bélanger, K., Savage, K. J. J., Wong, R., Smylie, M., Kamel‐Reid, S., Tron, V. A., Chen, B. E., Hunder, N. N. H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.0655 · Cited by 135
Muntasell, A., Rojo, F., Servitja, S., Rubio-Pérez, C., Cabo, M., Tamborero, D., Costa-García, M., Martinez‐García, M., Menéndez, S., Vázquez, I., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2365 · Cited by 130
Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model.
Iannone, R., Miele, L., Maiolino, P., Pinto, A., & Morello, S. (2014) · Europe PMC (PubMed Central) · Cited by 129
Molecular Mechanisms Directing Migration and Retention of Natural Killer Cells in Human Tissues
Castriconi, R., Carrega, P., Dondero, A., Bellora, F., Casu, B., Regis, S., Ferlazzo, G., & Bottino, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02324 · Cited by 125
Coupling of Glucose Deprivation with Impaired Histone H2B Monoubiquitination in Tumors
Urasaki, Y., Heath, L., & Xu, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036775 · Cited by 125
Pernot, S., Terme, M., Radosevic‐Robin, N., Castan, F., Badoual, C., Marcheteau, E., Penault-Llorca, F. M., Bouché, O., Bennouna, J., François, É., et al. (2019) · Gastric Cancer · doi:10.1007/s10120-019-00983-3 · Cited by 123
Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells
Kim, N., & Kim, H. S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02041 · Cited by 120
Takasaka, N., Seed, R. I., Cormier, A., Bondesson, A. J., Lou, J., Elattma, A., Ito, S., Yanagisawa, H., Hashimoto, M., Ma, R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122591 · Cited by 119
Degos, C., Heinemann, M., Barrou, J., Boucherit, N., Lambaudie, É., Savina, A., Gorvel, L., & Olive, D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00877 · Cited by 118
Inflammatory infiltrates and natural killer cell presence in human brain tumors
Stevens, A., Kloeter, I., & Roggendorf, W. (1988) · Cancer · Cited by 117
Galland, S., Vuille, J. A., Martin, P., Letovanec, I., Caignard, A., Fregni, G., & Stamenkovic, I. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.089 · Cited by 116
Murakami, T., Nakazawa, T., Natsume, A., Nishimura, F., Nakamura, M., Matsuda, R., Omoto, K., Tanaka, Y., SHIDA, Y., Park, Y.-S., et al. (2018) · Anticancer Research · doi:10.21873/anticanres.12824 · Cited by 111
Häusler, S. F., del Barrio, I. M., Diessner, J., Stein, R. G., Strohschein, J., Hönig, A., Dietl, J., & Wischhusen, J. (2014) · Europe PMC (PubMed Central) · Cited by 109
Messaoudene, M., Fregni, G., Fourmentraux-Neves, E., Chanal, J., Maubec, E., Mazouz-Dorval, S., Couturaud, B., Girod, A., Sastre‐Garau, X., Albert, S., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1303 · Cited by 106
Vallera, D. A., Zhang, B., Gleason, M., Oh, S., Weiner, L. M., Kaufman, D. S., McCullar, V., Miller, J. S., & Verneris, M. R. (2013) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2012.1329 · Cited by 105
Bellora, F., Castriconi, R., Dondero, A., Pessino, A. M., Nencioni, A., Liggieri, G., Moretta, L., Mantovani, A., Moretta, A., & Bottino, C. (2014) · European Journal of Immunology · doi:10.1002/eji.201344130 · Cited by 104
Yin, T., Wang, G., He, S., Liu, Q., Sun, J., & Wang, Y. (2015) · Cellular Immunology · doi:10.1016/j.cellimm.2015.11.009 · Cited by 104
Targeting Cancer Stem Cells with Natural Killer Cell Immunotherapy
Luna, J. I., Grossenbacher, S. K., Murphy, W. J., & Canter, R. J. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1271874 · Cited by 100
Sun, H., Liu, L., Huang, Q., Liu, H., Huang, M., Wang, J., Wen, H., Lin, R., Qu, K., Li, K., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0757 · Cited by 100
Evidence for immune defects in breast and lung cancer patients
Caraș, I., Grigorescu, A. C., Stăvaru, C., Radu, D. L., Mogos, I., Szegli, G., & Sălăgeanu, A. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0556-2 · Cited by 99
Ma, X., Holt, D. M., Kundu, N., Reader, J. C., Goloubeva, O. G., Take, Y., & Fulton, A. M. (2013) · OncoImmunology · doi:10.4161/onci.22647 · Cited by 99
Rodriguez-Ruiz, M. E., Rodríguez, I., Mayorga, L., Labiano, T., Barbés, B., Etxeberría, I., Ponz‐Sarvisé, M., Azpilikueta, A., Bolaños, E., Sanmamed, M. F., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0558 · Cited by 99
Oberg, H., Kellner, C., Gonnermann, D., Sebens, S., Bauerschlag, D., Gramatzki, M., Kabelitz, D., Peipp, M., & Wesch, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00814 · Cited by 96
Adoptive cell therapy using engineered natural killer cells
Rezvani, K. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0601-6 · Cited by 96
Li, T., Zhang, Q., Jiang, Y., Yu, J., Hu, Y., Mou, T., Chen, G., & Li, G. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1069936 · Cited by 94
Control of NK Cell Activation by Immune Checkpoint Molecules
Beldi‐Ferchiou, A., & Caillat‐Zucman, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102129 · Cited by 86
Targeting latency-associated peptide promotes antitumor immunity
Gabriely, G., da Cunha, A. P., Rezende, R. M., Kenyon, B. M., Madi, A., Vandeventer, T., Skillin, N. P., Rubino, S. J., Garo, L. P., Mazzola, M. A., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aaj1738 · Cited by 81
Tseng, H.-C., Bui, V. T., Man, Y., Cacalano, N. A., & Jewett, A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00269 · Cited by 80
Kozłowska, A. K., Topchyan, P., Kaur, K., Tseng, H.-C., Teruel, A., Hiraga, T., & Jewett, A. (2017) · Journal of Cancer · doi:10.7150/jca.15989 · Cited by 80
Enhanced targeting of stem-like solid tumor cells with radiation and natural killer cells
Ames, E., Canter, R. J., Grossenbacher, S. K., Mac, S., Smith, R. C., Monjazeb, A. M., Chen, M., & Murphy, W. J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1036212 · Cited by 77
Sanseviero, E., O’Brien, E. M., Karras, J. R., Shabaneh, T. B., Aksoy, B. A., Xu, W., Zheng, C., Yin, X., Xu, X., Karakousis, G. C., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0386 · Cited by 75
Cifaldi, L., Doria, M., Cotugno, N., Zicari, S., Cancrini, C., Palma, P., & Rossi, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153715 · Cited by 69
Self-citationSu, Y., Huang, X., Raskovalova, T., Zacharia, L. C., Lokshin, A. E., Jackson, E. K., & Gorelik, E. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0494-5 · Cited by 68
Yoshida, N., Ino, K., Ishida, Y., Kajiyama, H., Yamamoto, E., Shibata, K., Terauchi, M., Nawa, A., Akimoto, H., Takikawa, O., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0991 · Cited by 65
Oberschmidt, O., Kloeß, S., & Koehl, U. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00654 · Cited by 63
Long, Y., Gao, Z., Hu, X., Feng, X., Wu, Z., Zhang, J., Han, X., Yin, L., Qin, J., Lan, L., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1713 · Cited by 62
Liljefors, M., Nilsson, B. R., Hjelm, A., Ragnhammar, P., Mellstedt, H., & Frödin, J. (2003) · International Journal of Cancer · doi:10.1002/ijc.11139 · Cited by 61
Fink, T., Ebbesen, P., Koppelhus, U., & Zachar, V. (2003) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2003.01347.x · Cited by 60
TIM-3/Gal-9 interaction induces IFNγ-dependent IDO1 expression in acute myeloid leukemia blast cells
Folgiero, V., Cifaldi, L., Pira, G. L., Goffredo, B. M., Vinti, L., & Locatelli, F. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0134-4 · Cited by 60
Self-citationBoosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective
Cifaldi, L., Locatelli, F., Marasco, E., Moretta, L., & Pistoia, V. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.10.002 · Cited by 57
Self-citationBrandetti, E., Veneziani, I., Melaiu, O., Pezzolo, A., Castellano, A., Boldrini, R., Ferretti, E., Fruci, D., Moretta, L., Pistoia, V., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1316439 · Cited by 56
Self-citationSimpkins, F. A., Flores, A. E., Chu, C., Berek, J. S., Lucci, J. A., Murray, S. C., Bauman, J., Struemper, H., Germaschewski, F., Jonak, Z., et al. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0098 · Cited by 55
Turini, M., Chames, P., Bruhns, P., Baty, D., & Kerfélec, B. (2014) · Oncotarget · doi:10.18632/oncotarget.2093 · Cited by 54
KLRG1+ NK Cells Protect T-bet–Deficient Mice from Pulmonary Metastatic Colorectal Carcinoma
Malaisé, M., Rovira, J., Renner, P., Eggenhofer, E., Sabet-Baktach, M., Lantow, M., Lang, S. A., Koehl, G. E., Farkas, S. A., Loss, M., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1300876 · Cited by 54
Charrier, M., Mezquita, L., Lueza, B., Dupraz, L., Planchard, D., Remón, J., Caramella, C., Cassard, L., Boselli, L., Reiners, K. S., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.017 · Cited by 52
Lu, S., Zhang, J., Liu, D., Li, G., Staveley-O’Carroll, K. F., Li, Z., & Wu, J. D. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0845 · Cited by 47
Toll-like receptor 3 regulates NK cell responses to cytokines and controls experimental metastasis
Guillerey, C., Chow, M. T., Miles, K. M., Olver, S. D., Sceneay, J., Takeda, K., Möller, A., & Smyth, M. J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1027468 · Cited by 46
Grünwald, V., Desar, I. M. E., Haanen, J. B. A. G., Fiedler, W., Mouritzen, U., Olsen, M. W. B., & van Herpen, C. M. L. (2010) · Acta Oncologica · doi:10.3109/0284186x.2010.509104 · Cited by 42
Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy
Zhang, J., Liu, D., Li, G., Staveley-O’Carroll, K. F., Graff, J. N., Li, Z., & Wu, J. D. (2017) · Science Advances · doi:10.1126/sciadv.1602133 · Cited by 40
Muntasell, A., Servitja, S., Cabo, M., Bermejo, B., Pérez‐Buira, S., Rojo, F., Costa-García, M., Arpí, O., Moraru, M., Serrano, L., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0896 · Cited by 40
Kozłowska, A. K., Kaur, K., Topchyan, P., & Jewett, A. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1822-9 · Cited by 39
Merzoug, L. B., Marie, S., Satoh‐Takayama, N., Lesjean, S., Albanesi, M., Luche, H., Fehling, H. J., Santo, J. P. D., & Vosshenrich, C. A. J. (2014) · European Journal of Immunology · doi:10.1002/eji.201444643 · Cited by 38
Spender, L. C., Ferguson, G. J., Hughes, G. D., Davies, B. R., Goldberg, F. W., Herrera, B. M., Taylor, R. G., Strathearn, L. S., Sansom, O. J., Barry, S. T., et al. (2018) · Molecular Pharmacology · doi:10.1124/mol.118.112946 · Cited by 37
Cited by
Exploring the NK cell platform for cancer immunotherapy
Myers, J. A., & Miller, J. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0426-7 · Cited by 1,276
Roles of natural killer cells in immunity to cancer, and applications to immunotherapy
Wolf, N. K., Kissiov, D. U., & Raulet, D. H. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00732-1 · Cited by 577
The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies
Bald, T., Krummel, M. F., Smyth, M. J., & Barry, K. C. (2020) · Nature Immunology · doi:10.1038/s41590-020-0728-z · Cited by 506
A pan-cancer single-cell panorama of human natural killer cells
Tang, F., Li, J., Qi, L., Liu, D., Bo, Y., Qin, S., Miao, Y., Yu, K., Hou, W., Li, J., et al. (2023) · Cell · doi:10.1016/j.cell.2023.07.034 · Cited by 450
“However, NK-cell-based therapies are hindered in solid tumors partly due to the incomplete understanding of tumor-infiltrating NK cells, especially their infiltration to tumor, phenotypic heterogeneities, and dysregulation within the TME.(7,8) In humans, NK cells can be subdivided into two major groups, CD56CD16 and C…”
BackgroundInfluentialChimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
Gong, Y., Klein Wolterink, R. G. J., Wang, J., Bos, G. M. J., & Germeraad, W. T. V. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01083-5 · Cited by 379
Metadata
- Authors
- Melaiu, O., Lucarini, V., Cifaldi, L., & Fruci, D.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-01-21
- Volume
- 10
- Pages
- 3038-3038
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3001496296
- Cited by
- 419
- References
- 207
- FWCI
- 17.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.